The APPRenD MENTALWISE project (i-nov wave 6 competition), led by the company Semeia, aims to develop a digital phenotyping algorithm for two major psychiatric disorders: bipolar disorders and depression, then integrate it into the remote monitoring solution MentalWise from Semeia to improve and optimize patient care.
Supported and certified by Eurobiomed, financed by Bpifrance, the project has already made it possible to establish first predictive models making it possible to estimate the risk of stopping treatment, non-compliance and hospitalization of bipolar patients. A clinical study already including 800 bipolar patients is underway.